Prelude Therapeutics Incorporated
PRLD · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $12.1M | $7.00M | +73.4% |
| Operating income | −$105M | −$140M | +25.2% |
| Net income | −$99.5M | −$127M | +21.8% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 16, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $5.60M | $6.50M | −13.8% |
| Operating income | −$14.3M | −$20.4M | +29.9% |
| Net income | −$12.5M | −$19.7M | +36.5% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Prelude Therapeutics's revenue in FY2025?
- $12.1M in FY2025 (Fiscal year ended Dec 31, 2025), +73.4% vs $7.00M a year earlier, per its 10-K filed Mar 2026.
- Was Prelude Therapeutics profitable in FY2025?
- No: net income was −$99.5M and operating income −$105M in FY2025.
- What was Prelude Therapeutics's revenue in Q3 2026?
- $5.60M (−13.8% vs a year earlier), per its Form 10-Q filed Nov 16, 2026.